**Supplementary Table S2.** Clinical efficacy of Anlotinib combined with Anti-PD-1 Immunotherapy in advanced NSCLC patients

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| *n* (%) | |  | Anlotinib | Immunotherapy | A+P combination therapy | c2 | *P* |
| Efficacy | |  |  |  |  | 9.607 | 0.048\* |
|  | Complete response | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |  |  |
|  | Partial response | 40 (28.2%) | 10 (7.0%) | 7 (4.9%) | 23 (16.2%) |  |  |
|  | Stable disease | 61 (43.0%) | 24 (16.9%) | 13 (9.2%) | 24 (16.9%) |  |  |
|  | Progressive disease | 41 (28.9%) | 21 (14.8%) | 10 (7.0%) | 10 (7.0%) |  |  |
| Overall response rate | | 40 (28.2%) | 10 (7.0%) | 7 (4.9%) | 23 (16.2%) | 7.238 | 0.027\* |
| Disease Control Rate | | 101 (71.1%) | 34 (23.9%) | 20 (14.1%) | 47 (33.1%) | 6.174 | 0.046\* |
| \**P*< 0.05 | |  |  |  |  |  |  |